Top Ten Common Prejudices About Polyethylene Naphthalate Market.
TMR has released a new research named, ‘Hemostasis Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027.' The global hemostasis diagnostics market was worth US$ 2.3 billion in 2018, according to the report, and is expected to grow at an annual rate of 8.5 percent from 2019 to 2027. Coagulation disorders are problems with the body's capacity to clot blood. These conditions can result in bleeding or thrombosis. Coagulatory abnormalities can be caused by a variety of factors. These conditions can be acquired or hereditary. Hemophilia, von Willebrand disease, and platelet dysfunction are some of the most common coagulation diseases that can cause bleeding. Vitamin K insufficiency, disseminated intravascular coagulation, and other clotting factor shortages are further types of coagulation problems that can lead to bleeding. Hemophilia A is four times more frequent than haemophilia B, according to the National Hemophilia Foundation. The number of people living with haemophilia in the United States is believed to be around 20,000.
In 2018, the largest market for hemostasis diagnostics was North America. From 2017 to 2025, an increase in the prevalence of cardiovascular illnesses, deep vein thrombosis, and inherited and acquired blood clotting disorders is expected to drive the hemostasis diagnostics market in North America. In addition, technological developments, improved access to health-care services, and the entry of new manufacturers are all expected to boost the market in the area over the projection period.
During the projected period, Asia Pacific is expected to be a highly profitable market for hemostasis diagnostics, with a high CAGR. The use of diagnostic and therapeutic items in the region has expanded as a result of the region's high per capita income. The rapid growth of the industry in the region can be linked to a slew of government programmes aimed at improving the region's health-care infrastructure. Due to a movement in the base of pharmaceutical businesses and clinical research industries from developed to developing nations such as China and India, the market in the region is expected to grow fast in comparison to other regions.
Technology is evolving rapidly. In recent years, blood coagulation monitoring has become crucial to diagnosing causes of hemorrhages, developing anticoagulant drugs, assessing bleeding risk in extensive surgery procedures and dialysis, and investigating the efficacy of hemostatic therapies. Hemostasis diagnostics devices have come a long way from quantifying optical density of clot in a cuvette to detection of clotting factors. These include flow cytometry, chromogenic assays, molecular typing (e.g., polymerase chain reaction), immunologic assays (e.g., enzyme-linked immunosorbent assays), functional assays of specific coagulation proteins, and platelet function analyzers.
Bleeding disorders fall into two primary categories: inherited and acquired. Inherited bleeding disorders are caused by a lack of coagulation factors and are caused by a genetic predisposition. Acquired bleeding disorders can be caused by a variety of illnesses that might arise at any moment during a person's life. Hereditary bleeding disorders are caused by a lack or deficit of certain clotting proteins, which operate as procoagulants in the clotting cascade through precise interactions. Hemophilia A and B are the most well-known inherited bleeding disorders, however they are rather uncommon. Males with haemophilia A are 1 in 5000–10,000, while males with haemophilia B are 1 in 50,000–100,000.
The global hemostasis diagnostics market has been segmented into laboratory systems, consumables, and point-of-care testing systems based on product type. Laboratory systems are divided into three categories: automated, semi-automated, and manual.
The worldwide hemostasis diagnostics market was led by the consumables segment in 2018, and this trend is expected to continue over the forecast period. The expansion of the market is fueled by an increase in the use of kits and reagents, as well as numerous assays used for hemostasis diagnostics that deliver results in a short amount of time.
Point-of-care testing systems, on the other hand, deliver valid results in a shorter amount of time, making them the fastest-growing segment.
Comments
Post a Comment